Skip Navigation
Skip to contents

JYMS : Journal of Yeungnam Medical Science

Indexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
3 "Therapeutics"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Communication
Some suggestions for pain physicians working in real-world clinical settings
Jung Hwan Lee, Min Cheol Chang
J Yeungnam Med Sci. 2023;40(Suppl):S123-S124.   Published online May 23, 2023
DOI: https://doi.org/10.12701/jyms.2023.00255
  • 643 View
  • 32 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDF
Musculoskeletal pain is a common reason for patients visiting hospitals or clinics. Various therapeutic tools including oral medications, physical modalities, and procedures have been used to alleviate musculoskeletal pain. Numerous clinical trials have been conducted to demonstrate the therapeutic effect of each treatment and compare the efficacy of different protocols. These trials were conducted under controlled conditions with specific endpoints and timeframes, and the individual constraints of each patient were not considered. We believe that the findings of such studies may not accurately reflect clinical reality in real-world settings. In this article, we propose treatment principles for patients in pain clinics. We propose two principles for pain treatment: first, “Healing, in the end, is not healing.” and second, “The patient’s job is not a patient.” The main role of pain physicians is to quickly and actively reduce pain and help patients focus on their work and lives.

Citations

Citations to this article as recorded by  
  • Effectiveness of transcranial alternating current stimulation for controlling chronic pain: a systematic review
    Min Cheol Chang, Marie-Michèle Briand, Mathieu Boudier-Revéret, Seoyon Yang
    Frontiers in Neurology.2023;[Epub]     CrossRef
Review article
Diagnosis and treatment of multidrug-resistant tuberculosis
Jong Geol Jang, Jin Hong Chung
Yeungnam Univ J Med. 2020;37(4):277-285.   Published online September 4, 2020
DOI: https://doi.org/10.12701/yujm.2020.00626
  • 16,225 View
  • 533 Download
  • 43 Crossref
AbstractAbstract PDF
Tuberculosis (TB) is still a major health problem worldwide. Especially, multidrug-resistant TB (MDR-TB), which is defined as TB that shows resistance to both isoniazid and rifampicin, is a barrier in the treatment of TB. Globally, approximately 3.4% of new TB patients and 20% of the patients with a history of previous treatment for TB were diagnosed with MDR-TB. The treatment of MDR-TB requires medications for a long duration (up to 20–24 months) with less effective and toxic second-line drugs and has unfavorable outcomes. However, treatment outcomes are expected to improve due to the introduction of a new agent (bedaquiline), repurposed drugs (linezolid, clofazimine, and cycloserine), and technological advancement in rapid drug sensitivity testing. The World Health Organization (WHO) released a rapid communication in 2018, followed by consolidated guidelines for the treatment of MDR-TB in 2019 based on clinical trials and an individual patient data meta-analysis. In these guidelines, the WHO suggested reclassification of second-line anti-TB drugs and recommended oral treatment regimens that included the new and repurposed agents. The aims of this article are to review the treatment strategies of MDR-TB based on the 2019 WHO guidelines regarding the management of MDR-TB and the diagnostic techniques for detecting resistance, including phenotypic and molecular drug sensitivity tests.

Citations

Citations to this article as recorded by  
  • Computational insights into potential marine natural products as selective inhibitors of Mycobacterium tuberculosis InhA: A structure-based virtual screening study
    Manikandan Jayaraman, Vijayakumar Gosu, Rajalakshmi Kumar, Jeyakanthan Jeyaraman
    Computational Biology and Chemistry.2024; 108: 107991.     CrossRef
  • Targeting of essential mycobacterial replication enzyme DnaG primase revealed Mitoxantrone and Vapreotide as novel mycobacterial growth inhibitors**
    Waseem Ali, Salma Jamal, Rishabh Gangwar, Faraz Ahmed, Rahul Sharma, Meetu Agarwal, Javaid Ahmad Sheikh, Abhinav Grover, Sonam Grover
    Molecular Informatics.2024;[Epub]     CrossRef
  • A Comprehensive Review on Long vs. Short Regimens in Multidrug-Resistant Tuberculosis (MDR-TB) Under Programmatic Management of Drug-Resistant Tuberculosis (PMDT)
    Ashwin Karnan, Ulhas Jadhav, Babaji Ghewade, Anjana Ledwani, Poorna Shivashankar
    Cureus.2024;[Epub]     CrossRef
  • Design, synthesis and biological evaluation of novel pyrido-[2,3-d]-pyrimidin-2-amine analogues as antimycobacterial agents
    Boddupalli Venkata Siva Kumar, Yogesh Mahadu Khetmalis, Kosana Sai Chaitanya, Ala Chandu, Gauri Shetye, Rui Ma, Sankaranarayanan Murugesan, Scott G. Franzblau, Kondapalli Venkata Gowri Chandra Sekhar
    Journal of Molecular Structure.2024; 1303: 137600.     CrossRef
  • Direct TAMRA-dUTP labeling of M. tuberculosis genes using loop-mediated isothermal amplification (LAMP)
    Basma Altattan, Jasmin Ullrich, Emily Mattig, Aline Poppe, Renata Martins, Frank F. Bier
    Scientific Reports.2024;[Epub]     CrossRef
  • Antimicrobial peptides as new-generation antibiotics against Mycobacterium
    Parisa Eslami, Adnan Khosravi
    Journal of Preventive, Diagnostic and Treatment Strategies in Medicine.2024; 3(1): 6.     CrossRef
  • A Case of Multidrug-Resistant Tuberculosis in an Active Duty Military Health Care Worker
    Amanda E Saunders, Kevin M Shanahan, John W Downs
    Military Medicine.2024;[Epub]     CrossRef
  • Factors Associated with Non-Adherence to Treatment Among Migrants with MDR-TB in Wuhan, China: A Cross-Sectional Study
    Kunhe Lin, Li Xiang
    Risk Management and Healthcare Policy.2024; Volume 17: 727.     CrossRef
  • Development of a self-microemulsifying drug delivery system to deliver delamanid via a pressurized metered dose inhaler for treatment of multi-drug resistant pulmonary tuberculosis
    Himanshu Paliwal, Titpawan Nakpheng, Pijush Kumar Paul, K. Prem Ananth, Teerapol Srichana
    International Journal of Pharmaceutics.2024; 655: 124031.     CrossRef
  • Drug Targets, Current and Future Therapeutics for the Treatment of Multi Drug Resistant Tuberculosis with their Clinical Applications: A Critical Review
    Deepshikha Singh, Vikram Singh, Subhankar P. Mandal, Karen Dsouza, B.R. Prashantha Kumar, Sheshagiri R. Dixit
    Current Drug Therapy.2024; 19(3): 317.     CrossRef
  • Synthesis and Structure–Activity Relationship of 2,6-Disubstituted Thiosemicarbazone Derivatives of Pyridine as Potential Antituberculosis Agents
    Dagmara Ziembicka, Katarzyna Gobis, Małgorzata Szczesio, Andrzej Olczak, Ewa Augustynowicz-Kopeć, Agnieszka Głogowska, Izabela Korona-Głowniak, Krzysztof Bojanowski
    Materials.2023; 16(1): 448.     CrossRef
  • Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now
    Kona Chowdhury, Rahnuma Ahmad, Susmita Sinha, Siddhartha Dutta, Mainul Haque
    Cureus.2023;[Epub]     CrossRef
  • Anxiety and depression level of patients with multidrug-resistant tuberculosis (MDR-TB) in two hospitals in Banten province, Indonesia
    Tirta Darmawan Susanto, Allen Widysanto, Darien Alfa Cipta, Arron Tanara, Ghivarell Rizkie Wirawan, Adeline Bercadina Kosim, Christabella Maria Djoni, Ervinna Tantri, Chandni Kumar, Chelsie Angelius
    Dialogues in Health.2023; 2: 100115.     CrossRef
  • Characteristics of Previous Tuberculosis Treatment History in Patients with Treatment Failure and the Impact on Acquired Drug-Resistant Tuberculosis
    Soedarsono Soedarsono, Ni Made Mertaniasih, Tutik Kusmiati, Ariani Permatasari, Wiwik Kurnia Ilahi, Amelia Tantri Anggraeni
    Antibiotics.2023; 12(3): 598.     CrossRef
  • Evolution of tuberculosis diagnostics: From molecular strategies to nanodiagnostics
    Srestha Mukherjee, Summaya Perveen, Anjali Negi, Rashmi Sharma
    Tuberculosis.2023; 140: 102340.     CrossRef
  • Assessment of the Diagnostic Utility of GeneXpert Mycobacterium tuberculosis/Rifampicin (MTB/RIF) Assay in the Suspected Cases of Tuberculous Meningitis
    Sakshi Patel, Malti Dadheech, Anand K Maurya, Jitendra Singh, Shashank Purwar, Nirendra Rai, Radha Sarawagi, Ankur Joshi, Sagar Khadanga
    Cureus.2023;[Epub]     CrossRef
  • Tandem LC-MS Identification of Antitubercular Compounds in Zones of Growth Inhibition Produced by South African Filamentous Actinobacteria
    Daniel J. Watson, Lubbe Wiesner, Tlhalefo Matimela, Denzil Beukes, Paul R. Meyers
    Molecules.2023; 28(11): 4276.     CrossRef
  • Drug-Resistant Tuberculosis Stigma Among HealthCare Workers Toward the Development of a Stigma-Reduction Strategy: A Scoping Review
    Lolita Liboon Aranas, Khorshed Alam, Prajwal Gyawali, Rashidul Mahumud Alam
    INQUIRY: The Journal of Health Care Organization, Provision, and Financing.2023;[Epub]     CrossRef
  • Quality Mindset: The Missing Ingredient in Tuberculosis Care and Control in Togo
    Kossivi Agbélénko Afanvi, Mohammed Fall Dogo, Koffi Atsu Aziagbé, Komi Séraphin Adjoh, Koumavi Kristoli Didier Ekouévi
    European Journal of Theoretical and Applied Sciences.2023; 1(4): 36.     CrossRef
  • Machine Learning of the Whole Genome Sequence of Mycobacterium tuberculosis: A Scoping PRISMA-Based Review
    Ricardo Perea-Jacobo, Guillermo René Paredes-Gutiérrez, Miguel Ángel Guerrero-Chevannier, Dora-Luz Flores, Raquel Muñiz-Salazar
    Microorganisms.2023; 11(8): 1872.     CrossRef
  • Cotreatment With Clofazimine and Rapamycin Eliminates Drug-Resistant Tuberculosis by Inducing Polyfunctional Central Memory T-Cell Responses
    Dhiraj Kumar Singh, Ashima Bhaskar, Isha Pahuja, Aishwarya Shaji, Barnani Moitra, Yufang Shi, Ved Prakash Dwivedi, Gobardhan Das
    The Journal of Infectious Diseases.2023; 228(9): 1166.     CrossRef
  • Treatment of drug-resistant tuberculosis in children and young adolescents in Brazil
    Fernanda Bruzadelli Paulino da Costa, Thaís Zamboni Berra, Jaqueline Garcia de Almeida Ballestero, Patricia Bartholomay Oliveira, Daniele Maria Pelissari, Yan Mathias Alves, Antônio Carlos Vieira Ramos, Juliana Queiroz Rocha de Paiva, Titilade Kehinde Aya
    Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.2023; 33: 100388.     CrossRef
  • Tackling Drug-Resistant Tuberculosis: New Challenges from the Old Pathogen Mycobacterium tuberculosis
    Giuseppe Mancuso, Angelina Midiri, Silvia De Gaetano, Elena Ponzo, Carmelo Biondo
    Microorganisms.2023; 11(9): 2277.     CrossRef
  • Drug-resistant Monoarticular Wrist Joint Tuberculosis in Renal Transplant Recipient with Literature Review
    Jasmine Sethi, Vignesh Subramani, Rajender Kumar, Shivakumar Patil, Ashish Sharma
    Indian Journal of Transplantation.2023; 17(3): 371.     CrossRef
  • Predictive capabilities of baseline radiological findings for early and late disease outcomes within sensitive and multi-drug resistant tuberculosis cases
    Gabriel Rosenfeld, Andrei Gabrielian, Darrell Hurt, Alex Rosenthal
    European Journal of Radiology Open.2023; 11: 100518.     CrossRef
  • Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies
    Mahesh Kumar, Tarun Virmani, Girish Kumar, Rohitas Deshmukh, Ashwani Sharma, Sofia Duarte, Pedro Brandão, Pedro Fonte
    Pharmaceuticals.2023; 16(10): 1360.     CrossRef
  • A systematic review and meta-analysis on the correlation between HIV infection and multidrug-resistance tuberculosis
    Yulong Song, Qian Jin, Jihai Qiu, Dan Ye
    Heliyon.2023; 9(11): e21956.     CrossRef
  • Current Insights into Diagnosing and Treating Neurotuberculosis in Adults
    Sofiati Dian, Ahmad Rizal Ganiem, Lindsey HM te Brake, Arjan van Laarhoven
    CNS Drugs.2023; 37(11): 957.     CrossRef
  • Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis
    Temesgen Yihunie Akalu, Archie C. A. Clements, Haileab Fekadu Wolde, Kefyalew Addis Alene
    Scientific Reports.2023;[Epub]     CrossRef
  • Nano vs Resistant Tuberculosis: Taking the Lung Route
    Deepika Sharma, Pooja, Sunita Nirban, Smriti Ojha, Tarun Kumar, Neha Jain, Najwa Mohamad, Pradeep Kumar, Manisha Pandey
    AAPS PharmSciTech.2023;[Epub]     CrossRef
  • Multi-Drug Resistance Tuberculosis (MDR-TB) Challenges in India: A Review
    Deepak Vishwakarma, Abhay Gaidhane, Sweta Sahu, Ashwini S Rathod
    Cureus.2023;[Epub]     CrossRef
  • Multidrug-resistant Tuberculosis and its Implication with COVID-19
    Jasmine Arya, Sweety Dahiya, Anil Kumar Chhillar
    Coronaviruses.2023;[Epub]     CrossRef
  • Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance
    Summaya Perveen, Diksha Kumari, Kuljit Singh, Rashmi Sharma
    European Journal of Medicinal Chemistry.2022; 229: 114066.     CrossRef
  • Abdominal Tuberculosis Mimicking Ovarian Cancer: A Case Report and Review of the Literature
    Ikhwan Rinaldi, Abdul Muthalib, Djaja Gosal, Teguh Wijayadi, Barlian Sutedja, Tjondro Setiawan, Andika Gunawan, Nelly Susanto, Lingga Magdalena, Diah Rini Handjari, Fetisari Kurniawan, Aisyah Rifani, Kevin Winston
    International Medical Case Reports Journal.2022; Volume 15: 169.     CrossRef
  • Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?
    Lehlogonolo N. F. Maphalle, Bozena B. Michniak-Kohn, Modupe O. Ogunrombi, Oluwatoyin A. Adeleke
    Children.2022; 9(8): 1120.     CrossRef
  • Various approaches to improving adherence of patients with tuberculosis. Prospects for the use of additive technologies in TB practice
    A. G. Naumov, A. S. Shprykov
    PULMONOLOGIYA.2022; 34(1): 80.     CrossRef
  • Antimicrobial Peptides as Potential Anti-Tubercular Leads: A Concise Review
    Gabriel S. Oliveira, Raquel P. Costa, Paula Gomes, Maria Salomé Gomes, Tânia Silva, Cátia Teixeira
    Pharmaceuticals.2021; 14(4): 323.     CrossRef
  • Treatment of Human Babesiosis: Then and Now
    Isaline Renard, Choukri Ben Mamoun
    Pathogens.2021; 10(9): 1120.     CrossRef
  • Novel mutations detected from drug resistant Mycobacterium tuberculosis isolated from North East of Thailand
    Ei Phoo Thwe, Wises Namwat, Porntip Pinlaor, Kulrattana Rueangsak, Arunnee Sangka
    World Journal of Microbiology and Biotechnology.2021;[Epub]     CrossRef
  • On the Mechanism of Development of Autoimmune Diseases Following Exposure to Inactivated Mycobacterium tuberculosis
    SV Skupnevskiy, GM Trukhina, EG Pukhaeva, AK Badtiev, FK Rurua, FE Batagova, ZhG Farnieva
    ЗДОРОВЬЕ НАСЕЛЕНИЯ И СРЕДА ОБИТАНИЯ - ЗНиСО / PUBLIC HEALTH AND LIFE ENVIRONMENT.2021; : 76.     CrossRef
  • Oral regimen for multi-drug-resistant TB can promote patient-centred and community-based treatment
    Suman Saurabh, Pankaj Bhardwaj
    Journal of Family Medicine and Primary Care.2021; 10(12): 4607.     CrossRef
  • Adverse effects induced by second-line antituberculosis drugs: an update based on last WHO treatment recommendations for drug-resistant tuberculosis
    Ionela-Alina Grosu-Creangă, Antigona Carmen Trofor, Radu Adrian Crișan-Dabija, Daniela Robu-Popa, Cristina Mihaela Ghiciuc, Elena Cătălina Lupușoru
    Pneumologia.2021; 70(3): 117.     CrossRef
  • Advances in the science and treatment of respiratory diseases
    Jin Hong Chung
    Yeungnam University Journal of Medicine.2020; 37(4): 251.     CrossRef
Case report
Transpedal lymphatic embolization for lymphorrhea at the graft harvest site after coronary artery bypass grafting
Jung Guen Cha, Sang Yub Lee, Jihoon Hong, Hun Kyu Ryeom, Gab Chul Kim, Young Woo Do
Yeungnam Univ J Med. 2021;38(1):74-77.   Published online July 20, 2020
DOI: https://doi.org/10.12701/yujm.2020.00297
  • 4,530 View
  • 64 Download
  • 3 Crossref
AbstractAbstract PDF
Lymphorrhea is a rare but potentially severe complication that occurs after various surgical procedures. Untreated lymphorrhea may lead to wound dehiscence, infection, and prolonged hospital stay. Currently, there is no standard effective treatment. Early management usually includes leg elevation, drainage, and pressure dressing. However, these methods are associated with prolonged recovery and high recurrence rates. We report a case of lymphorrhea from a calf wound after endoscopic great saphenous vein (GSV) harvesting for coronary artery bypass grafting (CABG). The patient presented with intractable oozing from the postoperative wound on the right calf. Lymphorrhea perGsisted for 6 weeks despite negative-pressure wound therapy with a long-acting somatostatin. We performed unilateral pedal lymphangiography that confirmed wound lymphorrhea, followed by glue embolization. No recurrence was observed after 8 months of follow-up. This case report demonstrates the successful use of lymphangiography with glue embolization in the control of lymphorrhea after GSV harvesting for CABG.

Citations

Citations to this article as recorded by  
  • Supermicrosurgical lymphatic venous anastomosis for intractable lymphocele after great saphenous vein harvesting graft
    Hirofumi Imai, Shuhei Yoshida, Toshiro Mese, Solji Roh, Isao Koshima
    Journal of Vascular Surgery Cases, Innovations and Techniques.2022; 8(1): 45.     CrossRef
  • Update February 2021
    Francine Blei
    Lymphatic Research and Biology.2021; 19(1): 96.     CrossRef
  • Lymphatic complications after harvesting venous conduits in coronary artery bypass grafting surgery
    D. V. Manvelyan, Yu. Y. Vechersky, V. V. Zatolokin, M. S. Kuznetsov, B. N. Kozlov
    The Siberian Journal of Clinical and Experimental Medicine.2021; 36(3): 27.     CrossRef

JYMS : Journal of Yeungnam Medical Science